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Purpose or Objective: Hypopharyngeal squamous cell 
carcinoma (HPSCC) is rarely diagnosed in early stage due to 
the nonspecific nature of early symptoms. Since its rarity, 
few reports regarding the treatment outcome are available 
and the most optimal treatment for early stage HPSCC has 
not yet been clarified. We assessed patterns of failure and 
factors that influence failures. 
 
Material and Methods:  total of 36 patients with 
pathologically confirmed stage I (n = 10) and II (n = 26) 
treated between January 1992 and March 2014 were 
retrospectively reviewed. Ten patients (28%) received 
definitive RT delivered with a median fraction dose 2.1 
Gy(range, 1.8‒2.3 Gy) to median total dose 69.1 Gy (range, 
60.8‒70.2 Gy) (R group). Nineteen patients (53%) underwent 
surgery only (S group). Seven patients (19%) treated with 
surgery followed by postoperative RT with a median fraction 
dose of 1.8 Gy (range 1.8‒2.3 Gy) to median total dose was 
63.0 Gy (range, 54.0‒66.6 Gy) (PORT group). Twenty-six 
patients received surgery included mass excision/partial 
pharyngectomy (n = 20), total laryngectomy with partial 
pharyngectomy (n = 4), and total pharyngolaryngectomy (n = 
2). Additionally, 4 of S group had no elective neck node 
dissection, seven patients had ipsilateral and eight patients 
had bilateral dissection. All of 10 patients in the R group and 
in the PORT group received elective bilateral neck 
irradiation. 
 
Results: At a median follow-up of 48 months, the 5-year 
locoregional control rate (LRC) was 65%. Of the 36 patients, 5 
patients had local failure (LF), one had regional failure (RF), 
three had combined locoregional failure (LRF) and two had 
distant failure. No differences were observed in the 5-year 
LRC among three groups (R, S, and PORT = 67%, 52%, and 
100%;, P = 0.17). In the RT group, 3 patients experienced LF 
without RF. In the S group, 7 patients experienced LRF; 2 LF, 
1 RF, and 3 combined LRF. There was no LRF in the PORT 
group though resection margin status of patients in the PORT 
group were more risky than in the S group (Close/Positive 
margin 85% vs. 32%; P = 0.03) Patients with pyriform sinus 
apex extension showed a trend toward lower LRC (38% vs. 
76%; P = 0.09). Patients with bilaterally treated neck 
(Treated neck group) showed lower trend of RF rate (4% vs. 
27%; P= 0.08). Of the 10 patients who experienced LRF, 9 
patients were successfully salvaged and 5-yr LRC after 
salvage treatment was 80%. Although late events of 
gastrostomy or tracheostomy were observed in 8 patients; 2 
patients in the untreated or ipsilaterally treated neck group, 
6 patients in the treated neck group (18% vs. 24%; P = 0.70) 
 
Conclusion: Multimodal approach achieved favorable 
locoregional disease control despite of the risk factor. There 
is no difference in LRC between R group and S group. 
Prophylactic treatment of lymph nodes in the neck improves 
regional control in selected early HPSCC. Future research in 
the significance of tumor extension and elective neck 
treatment will be necessary to define the optimal treatment. 
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Purpose or Objective: We investigated 18F-
fluorodeoxyglucose positron emission tomography (PET)-
derived parameters as prognostic indices for disease 
progression and survival in locally advanced nasopharyngeal 
carcinoma (NPC) and the effect of high-dose radiotherapy for 
a subpopulation with PET-based poor prognoses. 
 
Material and Methods: Ninety-seven stage III and IVa–b NPC 
patients who underwent definitive treatment and PET were 
reviewed. For each primary, nodal and whole tumor, 
maximum standardized uptake value, metabolic tumor 
volume, and total lesion glycolysis (TLG) were evaluated. The 
primary endpoint was progression-free survival (PFS). PFS was 
calculated from the treatment start date to the date of 
disease progression, relapse, death from any cause, or last 
contact. Overall actuarial survival (OS) was calculated from 
the treatment start date to the date of death or the last 
follow-up. PFS and OS were calculated using the Kaplan–
Meier method. The Contal and O’Quigley method was 
performed to determine the cut-off value for the most useful 
PET parameter from the C-index and iAUC to allow for 
dichotomization in an objective manner. 
 
Results: The median follow-up duration among surviving 
patients was 47 months (range, 8–127). Based on the C-index 
(0.666) and iAUC (0.669), the whole tumor TLG was the most 
useful predictor for progression-free survival (PFS); the whole 
tumor TLG cut-off value showing the best predictive 
performance was 322.7. The low-whole tumor TLG group 
showed significantly higher 5-year PFS (77.0% vs. 43.0%, P < 
0.001), overall survival (OS) (85.7% vs. 54.0%, P = 0.003), 
loco-regional failure free survival (77.0% vs. 49.1%, P = 0.001) 
and distant-failure free survival (81.6% vs. 60.3%, P = 0.012) 
rates than the high-whole tumor TLG group. The whole tumor 
TLG was one of the significant prognostic factors for PFS (HR, 
0.29; 95% CI, 0.13–0.64; P = 0.002) and OS (HR, 0.29; 95% CI, 
0.11–0.79; P = 0.02) in multivariate analysis. Patients with 
low-whole tumor TLG showed higher 5-year PFS in the 
subgroup for only patients receiving intensity-modulated 
radiotherapy (77.4% vs. 53.0%, P = 0.01). In the subgroup of 
patients with high-whole tumor TLG, patients receiving an 
EQD2 ≥70 Gy showed significantly greater complete remission 
(71.4% vs. 33.3%, P = 0.03) and higher 5-year OS rates (74.7% 
vs. 19.6%, P = 0.02). 
 
Conclusion: Our findings demonstrated that the whole tumor 
TLG could be an independent prognostic factor and high-dose 
radiotherapy could improve outcomes for NPC showing high 
whole tumor TLG. 
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Purpose or Objective: The analysis of circulating cell free 
DNA (cfDNA) in plasma samples of cancer patients (‘liquid 
biopsy’) is an upcoming option in detecting cancer 
characteristics, dynamics, prognosis and recurrence. 
Combining quantitative analysis, genetic information and 
clinical data appears as a promising tool in personalised 
medicine. 
 
Material and Methods: In a prospective pilot study a total of 
9 patients with head and neck cancer (median age 64.7 
years) receiving primary radiochemotherapy were analysed 
regarding cfDNA dynamics and genetic alterations. Blood 
samples were taken prior to therapy, during therapy (week 
1,4,6) and 6 weeks after end of treatment. 
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Results: Sequencing results of the tumours in the first three 
analysed patients showed somatic alterations of the cell 
cycle (TP53, CDKN2B), PI3K; AKT; RAS signaling cascades 
(ERBB3, HRAS, VHL, MTOR), chromatin regulation (TET2, 
ARID1A, KMT2A, EZH2, MEN1), Notch signaling (FBXW7, 
NOTCH1) and DNA damage response (BRCA1/2, MLH1). The 
amount of cfDNA varied among patients and during 
treatment. Quantitatively, in 5 patients the amount of cfDNA 
increased during therapy (after week 1). In 4 patients no 
initial relevant change could be seen (stable after week 1). 
Currently patients are in follow up for evaluation of clinical 
outcome. 
 
Conclusion: Our initial results suggest that monitoring cfDNA 
identifies different patient subsets. As a proof of concept, 
detection of cfDNA is feasible and a potentially promising 
tool to identify tumour specific ‘finger prints’. Perspectively 
we hope to use cfDNA as a liquid biopsy and biomarker to 
identify individual tumour signatures to personalise 
treatments, detect mutations for targeted therapies and to 
monitor treatment response. 
 
EP-1075  
Squamous cell carcinoma of maxillary sinus : 25-years 
experience in a single institution 
S.H. Jeon
1Seoul National University Hospital, Radiation Oncology, 
Seoul, Korea Republic of 
1, H.G. Wu1, J.H. Kim1, C.I. Park1 
 
Purpose or Objective: To evaluate the clinical outomes to 
find optimal treatment and analyze prognostic factors for 
squamous cell carcinoma of maxillary sinus. 
 
Material and Methods: Between January 1990 and December 
2014, 97 patients with histoligcally proven squamous cell 
carcinoma of maxillary sinus without distant metastasis, 
treated with either radical surgery and adjuvant 
radiotherapy(Op+RT) or radical radiotherapy(RT). Median age 
at diangnosis was 61. There was no stage I patient and only 5 
patients were stage II, all treated with Op+RT. Among 
twenty-three patients with stage III disease, fifteen patients 
were treated with Op+RT and eight patients were treated 
with RT. For stage IVA cancer, thirty-three patients received 
Op+RT, and twenty-eight patients were treated with RT. All 
eight patients with stage IVB cancer were treated with RT. 
Neoadjuvant chemotherapy and concurrent chemotherapy 
were used in fourty-five and nineteen patients, respectively. 
 
Results: Median follow-up period after diagnosis was 30 
months for all patients. For stage III cancer, Op+RT showed 
better outcomes than RT (5-year OS : 63.8% vs. 29.2%, 
p=0.12; 5-year PFS : 43.2% vs. 18.8%, p=0.16), although not 
statistically significant. For stage IVA cancer, however, two 
treatment options showed comparable results (5-year OS : 
52.6% vs. 51.3%, p=0.80; 5-year PFS : 37.6% vs. 28.6%, 
p=0.53). Local failure was the most common pattern of 
failure, found in fourty-two of ninty-seven patients (43.3%). 
Proportion of regional failures in initially node-positive 
patients was 21.4% (three out of fourteen). For initially node-
negative cancer, regional failure was not observed in fifteen 
patients who received either neck dissection or neck 
irradiation, but in 14.7% (ten out of sixty-eight) who did not 
received neck treatment. In multivariate analysis, age 
younger than 60, positive resection margin and masticator 
space invasion were bad prognostic factors in Op+RT group. 
Masticator space invasion and subcutaneous tissue of cheek 
invasion were bad prognostic factors in RT group. 
 
Conclusion: In squamous cell carcinoma of maxillary sinus, 
radical surgery followed by adjuvant radiotherapy should be 
recommended for stage III disease. For stage IVA, however, 
radical radiotherapy can be a good alternative option to 
surgery. Prophylactic neck treatment for initially node 
negative patients can prevent regional recurrence, with 
absolute risk reduction of about 15%. Masticator space 
invasion was found to be a bad prognostic factor for both 
treatment arms. 
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Purpose or Objective: Due to a risk of 18 to 45% of occult 
nodal metastases in cN0 HNSCC patients, prophylactic neck 
irradiation is often mandatory. Anyway, it leads to a large 
irradiation of normal tissues because bilateral drainage is the 
rule in only 30 to 50 % of individuals. Moreover, 15 to 30 % of 
the tumors drain in unpredicted nodal basins (risk of 
geographical miss). SPECT/CT lymphoscintigraphy of sentinel 
lymph nodes (SLN) could help individualizing prophylactic 
irradiation levels in cN0 patients and, hence, reduce 
irradiated volume and improve quality of life (QoL). This 
ongoing prospective phase II study investigates its oncological 
safety.  
 
Material and Methods: Twenty-six patients with newly 
diagnosed cN0 SCC of the oral cavity, oropharynx, larynx or 
hypopharynx were included. All patients were imaged with 
SPECT/CT after 99mTc nanocolloid injection around the 
tumor. The neck levels containing up to four hottest SLN 
were identified and selected for prophylactic irradiation 
(CTVn-LS) by volumetric modulated arc therapy. A 
comparative virtual planning was performed with volumes 
selected according to international guidelines (CTVn-IG). QoL 
was assessed using EORTC C30 and HN25 scales. 
 
Results: Migration was observed in all of the 26 patients (one 
with gamma probe only) with an average of 2.8 sentinel 
nodes detected per patient. CTVn-LS was totally 
encompassed by CTVn-IG in all patients but two with an 
unpredicted drainage in homolateral retropharyngeal levels. 
More than half of the patients has only a unilateral drainage. 
CTVn-LS and related PTV were systematically smaller than IG 
ones, by a factor of two on average. This led to significant 
dose decrease in identified OAR as well as remaining volume 
at risk. With a median follow-up of 24 months, no regional 
relapse was observed while 3 patients had a local one (11%). 
Crude overall survival rate is 89%. QoL preliminary data will 
be presented. 
 
Conclusion: SPECT/CT lymphoscintigraphy of SLN allows 
individualizing prophylactic node CTV in cN0 HNSCC patients 
eligible for definitive radiotherapy. Both CTV and PTV are 
significantly reduced, which results in a significant dose 
decrease in OAR. At a median follow-up of 24 months, no 
regional relapse was observed but further follow-up and 
recruitment are necessary to ensure the oncological safety. 
QoL data are being analyzed. 
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Purpose or Objective: The aim of this study is to identify 
prognostic factors of treatment related toxicity after 
